24/03/2026
🧠 Redefining Alzheimer’s Diagnosis: Paradigm Shift from Late Detection to Early Precision
For decades, Alzheimer’s disease has been diagnosed too late—often when cognitive decline has already impacted daily life.
But today, the paradigm is changing.
At Agappe Diagnostics, we are bringing advanced biomarker-based testing closer to clinical practice—enabling earlier, more accurate detection and better clinical decision-making.
🔬 What’s changing?
Traditionally, diagnosis relied on clinical symptoms and imaging. However, subtle pathological changes begin years before symptoms appear.
With the advent of blood-based and CSF biomarkers, we can now detect these changes much earlier.
🧪 Our advanced diagnostic offerings include:
✔️ Blood-based biomarkers
* Plasma pTau217 / Aβ1-42 ratio – a powerful tool for identifying amyloid pathology
* Enables minimally invasive, scalable screening
✔️ CSF-based biomarkers
* Aβ42 / Aβ40 ratio – early indicator of amyloid deposition
* pTau181 – marker of tau pathology
* Total Tau (tTau) – reflects neurodegeneration
📌 Why does this matter?
Because the future of Alzheimer’s treatment is evolving.
Emerging therapies, including monoclonal antibodies targeting amyloid, are expected to transform disease management. However, their success depends on identifying the right patients at the right stage.
👉 Patients in early or preclinical stages
👉 Patients with confirmed amyloid pathology
👉 Patients who will truly benefit from targeted therapy
Without biomarkers, this precision is not possible.
🌍 As India prepares for the introduction of these therapies, the need for accurate, accessible diagnostics becomes even more critical.
At Agappe Diagnostics, we are committed to:
✔️ Enabling early detection
✔️ Supporting clinical decision-making
✔️ Preparing healthcare systems for the next era of Alzheimer’s care
Because the goal is no longer just diagnosis.
It is timely intervention, better outcomes, and hope.
